Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition

Stock Track

Nov 14, 2025

Shares of Cidara Therapeutics (CDTX) surged 13.63% in after-hours trading on Thursday, as news broke about a potential acquisition by pharmaceutical giant Merck. The significant jump in stock price comes amid reports that Merck is nearing a deal to acquire the flu treatment start-up.

According to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics. The deal is expected to value Cidara at a premium to its current market capitalization of $3.3 billion, highlighting the potential value Merck sees in Cidara's flu treatment technology. This premium valuation is likely the primary driver behind the stock's impressive after-hours performance.

Investors and market watchers are eagerly anticipating further details, as sources suggest the announcement could come as soon as Friday. The imminent nature of the potential deal has created a buzz in the pharmaceutical sector, with many seeing this as a strategic move by Merck to bolster its position in the flu treatment market. As always, investors are advised to stay tuned for official announcements and to consider the inherent risks associated with pre-deal stock movements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1182270368"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182270368\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182270368?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182270368","market":"sg","top_or_hot":-1,"title":"Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition","media":"Stock Track","content":"<p>Shares of Cidara Therapeutics (CDTX) surged 13.63% in after-hours trading on Thursday, as news broke about a potential acquisition by pharmaceutical giant Merck. The significant jump in stock price comes amid reports that Merck is nearing a deal to acquire the flu treatment start-up.</p>\n\n<p>According to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics. The deal is expected to value Cidara at a premium to its current market capitalization of $3.3 billion, highlighting the potential value Merck sees in Cidara's flu treatment technology. This premium valuation is likely the primary driver behind the stock's impressive after-hours performance.</p>\n\n<p>Investors and market watchers are eagerly anticipating further details, as sources suggest the announcement could come as soon as Friday. The imminent nature of the potential deal has created a buzz in the pharmaceutical sector, with many seeing this as a strategic move by Merck to bolster its position in the flu treatment market. As always, investors are advised to stay tuned for official announcements and to consider the inherent risks associated with pre-deal stock movements.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 07:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Cidara Therapeutics (CDTX) surged 13.63% in after-hours trading on Thursday, as news broke about a potential acquisition by pharmaceutical giant Merck. The significant jump in stock price comes amid reports that Merck is nearing a deal to acquire the flu treatment start-up.</p>\n\n<p>According to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics. The deal is expected to value Cidara at a premium to its current market capitalization of $3.3 billion, highlighting the potential value Merck sees in Cidara's flu treatment technology. This premium valuation is likely the primary driver behind the stock's impressive after-hours performance.</p>\n\n<p>Investors and market watchers are eagerly anticipating further details, as sources suggest the announcement could come as soon as Friday. The imminent nature of the potential deal has created a buzz in the pharmaceutical sector, with many seeing this as a strategic move by Merck to bolster its position in the flu treatment market. As always, investors are advised to stay tuned for official announcements and to consider the inherent risks associated with pre-deal stock movements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDTX","symbol_name":"Cidara Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1182270368","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182270368","pubTimestamp":1763076505,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cidara Therapeutics (CDTX) surged 13.63% in after-hours trading on Thursday, as news broke about a potential acquisition by pharmaceutical giant Merck. The significant jump in stock price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDTX":"Cidara Therapeutics, Inc."},"translate_title":"个股追踪|Cidara Therapeutics盘后大涨13.63%因潜在收购默沙东","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDTX":1},"content_text":"Shares of Cidara Therapeutics (CDTX) surged 13.63% in after-hours trading on Thursday, as news broke about a potential acquisition by pharmaceutical giant Merck. The significant jump in stock price comes amid reports that Merck is nearing a deal to acquire the flu treatment start-up.\nAccording to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics. The deal is expected to value Cidara at a premium to its current market capitalization of $3.3 billion, highlighting the potential value Merck sees in Cidara's flu treatment technology. This premium valuation is likely the primary driver behind the stock's impressive after-hours performance.\nInvestors and market watchers are eagerly anticipating further details, as sources suggest the announcement could come as soon as Friday. The imminent nature of the potential deal has created a buzz in the pharmaceutical sector, with many seeing this as a strategic move by Merck to bolster its position in the flu treatment market. As always, investors are advised to stay tuned for official announcements and to consider the inherent risks associated with pre-deal stock movements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}